Abstract：
The objectives are to know the opinion of neurologists and hospital pharmacists on those aspects still under debate regarding the role of anti-Calcitonin Gene-related Peptide monoclonal antibodies in the preventive treatment of migraine. To identify those controversies that still exist. To propose agreed recommendations for improvement of care. And to promote access of clinicians and patients to these new treatments in the prevention of migraine with biological drugs, in order to improve patient care and follow-up.
Recommendations for the use of biological drugs in the prevention of migraine were identified and evaluated through the Delphi consensus methodology, proposing 88 statements grouped into 3 themes: a clinical module that deals with the management of biological treatments in migraine; a patient module that discusses patient education and adherence improvement strategies; and a coordination module that includes statements related to strategies to improve joint work between the two groups. The 9-point Likert ordinal scale was used to score these recommendations and, subsequently, the data was statistically analysed through different metrics.
After both rounds of voting, consensus was reached in agreement on 71 of the 88 statements (80.7%), leaving 1 statement (1.1%) with consensus in disagreement and 16 remaining as indeterminate (18.2%).
The high degree of consensus indicates that the opinion of neurologists and hospital pharmacists on the role of anti-Calcitonin Gene-related Peptide monoclonal antibodies in the preventive treatment of migraine is very similar and allows identifying those controversies that still exist, to improve the care and follow-up of patients with migraine.
Recommendations for the use of biological drugs in the prevention of migraine were identified and evaluated through the Delphi consensus methodology, proposing 88 statements grouped into 3 themes: a clinical module that deals with the management of biological treatments in migraine; a patient module that discusses patient education and adherence improvement strategies; and a coordination module that includes statements related to strategies to improve joint work between the two groups. The 9-point Likert ordinal scale was used to score these recommendations and, subsequently, the data was statistically analysed through different metrics.
After both rounds of voting, consensus was reached in agreement on 71 of the 88 statements (80.7%), leaving 1 statement (1.1%) with consensus in disagreement and 16 remaining as indeterminate (18.2%).
The high degree of consensus indicates that the opinion of neurologists and hospital pharmacists on the role of anti-Calcitonin Gene-related Peptide monoclonal antibodies in the preventive treatment of migraine is very similar and allows identifying those controversies that still exist, to improve the care and follow-up of patients with migraine.
摘要：
目的：目的是了解神经科医师和医院药剂师关于抗降钙素基因相关肽单克隆抗体在偏头痛预防性治疗中的作用仍在争论中的观点。找出那些仍然存在的争议。提出改善护理的商定建议。为了促进临床医生和患者获得这些新的治疗方法，用生物药物预防偏头痛，以改善患者护理和随访。
方法：通过德尔菲共识方法确定并评估了在预防偏头痛中使用生物药物的建议，提出了88项陈述，分为3个主题：一个临床模块，涉及偏头痛的生物治疗管理；一个患者模块，讨论患者教育和依从性改善策略；以及一个协调模块，包括与改善两组之间联合工作的策略相关的陈述。使用9点Likert序数量表对这些建议进行评分，随后,通过不同指标对数据进行统计分析。
结果：经过两轮投票，就88项声明中的71项(80.7%)达成共识，留下1份声明(1.1%)存在共识分歧，16份仍不确定(18.2%)。
结论：高度的共识表明，神经科医生和医院药剂师关于抗降钙素基因相关肽单克隆抗体在偏头痛预防性治疗中的作用的观点非常相似，可以确定仍然存在的争议，改善偏头痛患者的护理和随访。
方法：通过德尔菲共识方法确定并评估了在预防偏头痛中使用生物药物的建议，提出了88项陈述，分为3个主题：一个临床模块，涉及偏头痛的生物治疗管理；一个患者模块，讨论患者教育和依从性改善策略；以及一个协调模块，包括与改善两组之间联合工作的策略相关的陈述。使用9点Likert序数量表对这些建议进行评分，随后,通过不同指标对数据进行统计分析。
结果：经过两轮投票，就88项声明中的71项(80.7%)达成共识，留下1份声明(1.1%)存在共识分歧，16份仍不确定(18.2%)。
结论：高度的共识表明，神经科医生和医院药剂师关于抗降钙素基因相关肽单克隆抗体在偏头痛预防性治疗中的作用的观点非常相似，可以确定仍然存在的争议，改善偏头痛患者的护理和随访。
